{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T04:57:48Z","timestamp":1768712268931,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"38","license":[{"start":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:00:00Z","timestamp":1627603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:00:00Z","timestamp":1627603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","award":["509233"],"award-info":[{"award-number":["509233"]}],"id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2021,9,23]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Melanomas driven by loss of the NF1 tumor suppressor have a high risk of treatment failure and effective therapies have not been developed. Here we show that loss-of-function mutations of <jats:italic>nf1<\/jats:italic> and <jats:italic>pten<\/jats:italic> result in aggressive melanomas in zebrafish, representing the first animal model of NF1-mutant melanomas harboring PTEN loss. MEK or PI3K inhibitors show little activity when given alone due to cross-talk between the pathways, and high toxicity when given together. The mTOR inhibitors, sirolimus, everolimus, and temsirolimus, were the most active single agents tested, potently induced tumor-suppressive autophagy, but not apoptosis. Because addition of the BCL2 inhibitor venetoclax resulted in compensatory upregulation of MCL1, we established a three-drug combination composed of sirolimus, venetoclax, and the MCL1 inhibitor S63845. This well-tolerated drug combination potently and synergistically induces apoptosis in both zebrafish and human NF1\/PTEN-deficient melanoma cells, providing preclinical evidence justifying an early-stage clinical trial in patients with NF1\/PTEN-deficient melanoma.<\/jats:p>","DOI":"10.1038\/s41388-021-01926-y","type":"journal-article","created":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T14:04:36Z","timestamp":1627653876000},"page":"5718-5729","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1\/PTEN loss"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0747-2425","authenticated-orcid":false,"given":"Shuning","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2489-3889","authenticated-orcid":false,"given":"Mark W.","family":"Zimmerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8583-620X","authenticated-orcid":false,"given":"Hillary M.","family":"Layden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alla","family":"Berezovskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Etchin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan W.","family":"Martel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Thurston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Bin","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"van Rooijen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles K.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott J.","family":"Rodig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0860-926X","authenticated-orcid":false,"given":"Leonard I.","family":"Zon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Elizabeth","family":"Patton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6835-3791","authenticated-orcid":false,"given":"Marc R.","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7851-8617","authenticated-orcid":false,"given":"A. Thomas","family":"Look","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,30]]},"reference":[{"key":"1926_CR1","first-page":"7","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: Cancer J Clinic. 2020;70:7\u201330.","journal-title":"CA: Cancer J Clinic"},{"key":"1926_CR2","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"R Akbani","year":"2015","unstructured":"Akbani R, Akdemir Kadir C, Aksoy BA, Albert M, Ally A, Amin Samirkumar B, et al. Genomic classification of cutaneous melanoma. Cell. 2015;161:1681\u201396.","journal-title":"Cell"},{"key":"1926_CR3","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1158\/2159-8290.CD-12-0313","volume":"3","author":"O Maertens","year":"2013","unstructured":"Maertens O, Johnson B, Hollstein P, Frederick DT, Cooper ZA, Messiaen L, et al. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov. 2013;3:338\u201349.","journal-title":"Cancer Discov"},{"key":"1926_CR4","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1158\/2159-8290.CD-12-0470","volume":"3","author":"SR Whittaker","year":"2013","unstructured":"Whittaker SR, Theurillat J-P, Van Allen E, Wagle N, Hsiao J, Cowley GS, et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov. 2013;3:350\u201362.","journal-title":"Cancer Discov"},{"key":"1926_CR5","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature22071","volume":"545","author":"NK Hayward","year":"2017","unstructured":"Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545:175\u201380.","journal-title":"Nature"},{"key":"1926_CR6","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/ng.3361","volume":"47","author":"M Krauthammer","year":"2015","unstructured":"Krauthammer M, Kong Y, Bacchiocchi A, Evans P, Pornputtapong N, Wu C, et al. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat Genet. 2015;47:996\u20131002.","journal-title":"Nat Genet"},{"key":"1926_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jbior.2014.04.002","volume":"55","author":"O Maertens","year":"2014","unstructured":"Maertens O, Cichowski K. An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer. Adv Biol Regulation. 2014;55:1\u201314.","journal-title":"Adv Biol Regulation"},{"key":"1926_CR8","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/1878-0261.12050","volume":"11","author":"H Cirenajwis","year":"2017","unstructured":"Cirenajwis H, Lauss M, Ekedahl H, Torngren T, Kvist A, Saal LH, et al. NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics. Mol Oncol. 2017;11:438\u201351.","journal-title":"Mol Oncol"},{"key":"1926_CR9","first-page":"81","volume":"8","author":"OF Kuzu","year":"2015","unstructured":"Kuzu OF, Nguyen FD, Noory MA, Sharma A. Current state of animal (mouse) modeling in melanoma research. Cancer Growth Metastasis. 2015;8:81\u201394.","journal-title":"Cancer Growth Metastasis"},{"key":"1926_CR10","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/978-3-319-30654-4_19","volume":"916","author":"CK Kaufman","year":"2016","unstructured":"Kaufman CK. Zebrafish melanoma. Adv Exp Med Biol. 2016;916:439\u201350.","journal-title":"Adv Exp Med Biol"},{"key":"1926_CR11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","volume":"150","author":"E Hodis","year":"2012","unstructured":"Hodis E, Watson Ian R, Kryukov Gregory V, Arold Stefan T, Imielinski M, Theurillat J-P, et al. A landscape of driver mutations in melanoma. Cell. 2012;150:251\u201363.","journal-title":"Cell"},{"key":"1926_CR12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature13561","volume":"514","author":"T De Raedt","year":"2014","unstructured":"De Raedt T, Beert E, Pasmant E, Luscan A, Brems H, Ortonne N, et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature. 2014;514:247\u201351.","journal-title":"Nature"},{"key":"1926_CR13","first-page":"881","volume":"5","author":"J Shin","year":"2012","unstructured":"Shin J, Padmanabhan A, de Groh ED, Lee J-S, Haidar S, Dahlberg S, et al. Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development. Dis Models Mech. 2012;5:881\u201394.","journal-title":"Dis Models Mech"},{"key":"1926_CR14","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1016\/j.celrep.2017.10.052","volume":"21","author":"B Garman","year":"2017","unstructured":"Garman B, Anastopoulos IN, Krepler C, Brafford P, Sproesser K, Jiang Y, et al. Genetic and genomic characterization of 462 melanoma patient-derived xenografts, tumor biopsies, and cell lines. Cell Rep. 2017;21:1936\u201352.","journal-title":"Cell Rep"},{"key":"1926_CR15","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.1158\/1078-0432.CCR-13-0398","volume":"19","author":"VJ Mar","year":"2013","unstructured":"Mar VJ, Wong SQ, Li J, Scolyer RA, McLean C, Papenfuss AT, et al. BRAF\/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. Clin Cancer Res. 2013;19:4589\u201398.","journal-title":"Clin Cancer Res"},{"key":"1926_CR16","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/sj.onc.1210730","volume":"27","author":"A Faucherre","year":"2007","unstructured":"Faucherre A, Taylor GS, Overvoorde J, Dixon JE, Hertog JD. Zebrafish pten genes have overlapping and non-redundant functions in tumorigenesis and embryonic development. Oncogene. 2007;27:1079\u201386.","journal-title":"Oncogene"},{"key":"1926_CR17","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1084\/jem.20101691","volume":"208","author":"A Gutierrez","year":"2011","unstructured":"Gutierrez A, Grebliunaite R, Feng H, Kozakewich E, Zhu S, Guo F, et al. Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. J Exp Med. 2011;208:1595\u2013603.","journal-title":"J Exp Med"},{"key":"1926_CR18","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nature09806","volume":"471","author":"CJ Ceol","year":"2011","unstructured":"Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando DA, Battisti V, et al. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature. 2011;471:513\u20137.","journal-title":"Nature"},{"key":"1926_CR19","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1089\/zeb.2009.0606","volume":"6","author":"M Dovey","year":"2009","unstructured":"Dovey M, White RM, Zon LI. Oncogenic NRAS cooperates with p53 Loss to Generate Melanoma in Zebrafish. Zebrafish. 2009;6:397\u2013404.","journal-title":"Zebrafish"},{"key":"1926_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/jid.2013.293","volume":"134","author":"JA Lister","year":"2014","unstructured":"Lister JA, Capper A, Zeng Z, Mathers ME, Richardson J, Paranthaman K, et al. A conditional zebrafish MITF mutation reveals MITF levels are critical for melanoma promotion vs. regression in vivo. J Investig Dermatol. 2014;134:133\u201340.","journal-title":"J Investig Dermatol"},{"key":"1926_CR21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.cub.2005.01.031","volume":"15","author":"E Patton","year":"2005","unstructured":"Patton E, Widlund H, Kutok J, Kopani K, Amatruda J, Murphey R, et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol. 2005;15:249\u201354.","journal-title":"Curr Biol"},{"key":"1926_CR22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nrc1819","volume":"6","author":"M Cully","year":"2006","unstructured":"Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 2006;6:184\u201392.","journal-title":"Nat Rev Cancer"},{"key":"1926_CR23","doi-asserted-by":"publisher","first-page":"10358.","DOI":"10.1038\/ncomms10358","volume":"7","author":"Q Tang","year":"2016","unstructured":"Tang Q, Moore JC, Ignatius MS, Tenente IM, Hayes MN, Garcia EG, et al. Imaging tumour cell heterogeneity following cell transplantation into optically clear immune-deficient zebrafish. Nat Commun. 2016;7:10358.","journal-title":"Nat Commun"},{"key":"1926_CR24","doi-asserted-by":"crossref","unstructured":"Kaufman CK, Mosimann C, Fan ZP, Yang S, Thomas AJ, Ablain J, et al. A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation. Science. 2016;351:aad2197.","DOI":"10.1126\/science.aad2197"},{"key":"1926_CR25","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","volume":"6","author":"W Peng","year":"2016","unstructured":"Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 2016;6:202\u201316.","journal-title":"Cancer Discov"},{"key":"1926_CR26","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1093\/jnci\/djp259","volume":"101","author":"KG Chen","year":"2009","unstructured":"Chen KG, Leapman RD, Zhang G, Lai B, Valencia JC, Cardarelli CO, et al. Influence of melanosome dynamics on melanoma drug sensitivity. J Natl Cancer Inst. 2009;101:1259\u201371.","journal-title":"J Natl Cancer Inst"},{"key":"1926_CR27","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","volume":"36","author":"MC Mendoza","year":"2011","unstructured":"Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochemical Sci. 2011;36:320\u20138.","journal-title":"Trends Biochemical Sci"},{"key":"1926_CR28","doi-asserted-by":"publisher","first-page":"e26343","DOI":"10.1371\/journal.pone.0026343","volume":"6","author":"S Yang","year":"2011","unstructured":"Yang S, Xiao X, Meng X, Leslie KK. A mechanism for synergy with combined mTOR and PI3 kinase inhibitors. PLoS ONE. 2011;6:e26343.","journal-title":"PLoS ONE"},{"key":"1926_CR29","doi-asserted-by":"publisher","first-page":"10034","DOI":"10.3390\/ijms150610034","volume":"15","author":"K Sharma","year":"2014","unstructured":"Sharma K, Le N, Alotaibi M, Gewirtz DA. Cytotoxic autophagy in cancer therapy. Int J Mol Sci. 2014;15:10034\u201351.","journal-title":"Int J Mol Sci"},{"key":"1926_CR30","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1159\/000442589","volume":"103","author":"S Avniel-Polak","year":"2016","unstructured":"Avniel-Polak S, Leibowitz G, Riahi Y, Glaser B, Gross DJ, Grozinsky-Glasberg S. Abrogation of autophagy by chloroquine alone or in combination with mTOR inhibitors induces apoptosis in neuroendocrine tumor cells. Neuroendocrinology. 2016;103:724\u201337.","journal-title":"Neuroendocrinology"},{"key":"1926_CR31","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s00432-014-1628-0","volume":"140","author":"M Kaneko","year":"2014","unstructured":"Kaneko M, Nozawa H, Hiyoshi M, Tada N, Murono K, Nirei T, et al. Temsirolimus and chloroquine cooperatively exhibit a potent antitumor effect against colorectal cancer cells. J Cancer Res Clin Oncol. 2014;140:769\u201381.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1926_CR32","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.4161\/auto.29119","volume":"10","author":"R Rangwala","year":"2014","unstructured":"Rangwala R, Chang YC, Hu J, Algazy KM, Evans TL, Fecher LA, et al. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy. 2014;10:1391\u2013402.","journal-title":"Autophagy"},{"key":"1926_CR33","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.semcancer.2013.05.006","volume":"23","author":"RL Macintosh","year":"2013","unstructured":"Macintosh RL, Ryan KM. Autophagy in tumour cell death. Semin Cancer Biol. 2013;23:344\u201351.","journal-title":"Semin Cancer Biol"},{"key":"1926_CR34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1101\/sqb.2016.81.030841","volume":"81","author":"DS Potter","year":"2016","unstructured":"Potter DS, Letai A. To prime, or not to prime: that is the question. Cold Spring Harb symposia Quant Biol. 2016;81:131\u201340.","journal-title":"Cold Spring Harb symposia Quant Biol"},{"key":"1926_CR35","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1158\/1535-7163.MCT-10-0427","volume":"9","author":"LT Lam","year":"2010","unstructured":"Lam LT, Lu X, Zhang H, Lesniewski R, Rosenberg S, Semizarov D. A microRNA screen to identify modulators of sensitivity to BCL2 inhibitor ABT-263 (navitoclax). Mol Cancer Ther. 2010;9:2943\u201350.","journal-title":"Mol Cancer Ther"},{"key":"1926_CR36","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S0092-8674(02)00762-6","volume":"109","author":"GG McGill","year":"2002","unstructured":"McGill GG, Horstmann M, Widlund HR, Du J, Motyckova G, Nishimura EK, et al. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell. 2002;109:707\u201318.","journal-title":"Cell"},{"key":"1926_CR37","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/pcmr.12242","volume":"27","author":"N Mohana-Kumaran","year":"2014","unstructured":"Mohana-Kumaran N, Hill DS, Allen JD, Haass NK. Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy. Pigment Cell Melanoma Res. 2014;27:525\u201339.","journal-title":"Pigment Cell Melanoma Res"},{"key":"1926_CR38","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1038\/jid.2015.145","volume":"135","author":"N Mukherjee","year":"2015","unstructured":"Mukherjee N, Schwan JV, Fujita M, Norris DA, Shellman YG. Alternative treatments for melanoma: targeting BCL-2 family members to de-bulk and kill cancer stem cells. J Investig Dermatol. 2015;135:2155\u201361.","journal-title":"J Investig Dermatol"},{"key":"1926_CR39","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1158\/2159-8290.CD-17-0797","volume":"7","author":"JD Leverson","year":"2017","unstructured":"Leverson JD, Sampath D, Souers AJ, Rosenberg SH, Fairbrother WJ, Amiot M, et al. Found in translation: how preclinical research is guiding the clinical development of the BCL2-selective inhibitor venetoclax. Cancer Discov. 2017;7:1376\u201393.","journal-title":"Cancer Discov"},{"key":"1926_CR40","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature19830","volume":"538","author":"A Kotschy","year":"2016","unstructured":"Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016;538:477\u201382.","journal-title":"Nature"},{"key":"1926_CR41","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41375-018-0201-2","volume":"33","author":"Z Li","year":"2019","unstructured":"Li Z, He S, Look AT. The MCL1-specific inhibitor S63845 acts synergistically with venetoclax\/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells. Leukemia. 2019;33:262\u20136.","journal-title":"Leukemia"},{"key":"1926_CR42","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/ng0293-118","volume":"3","author":"LB Andersen","year":"1993","unstructured":"Andersen LB, Fountain JW, Gutmann DH, Tarle SA, Glover TW, Dracopoli NC, et al. Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines. Nat Genet. 1993;3:118\u201321.","journal-title":"Nat Genet"},{"key":"1926_CR43","doi-asserted-by":"publisher","first-page":"5539","DOI":"10.1073\/pnas.90.12.5539","volume":"90","author":"MR Johnson","year":"1993","unstructured":"Johnson MR, Look AT, DeClue JE, Valentine MB, Lowy DR. Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP.Ras. Proc Natl Acad Sci USA. 1993;90:5539\u201343.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1926_CR44","doi-asserted-by":"publisher","first-page":"4649","DOI":"10.1158\/1078-0432.CCR-09-0317","volume":"15","author":"KP Hoeflich","year":"2009","unstructured":"Hoeflich KP, O\u2019Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res. 2009;15:4649\u201364.","journal-title":"Clin Cancer Res"},{"key":"1926_CR45","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/path.4013","volume":"227","author":"S He","year":"2012","unstructured":"He S, Lamers GEM, Beenakker J-WM, Cui C, Ghotra VPS, Danen EHJ, et al. Neutrophil-mediated experimental metastasis is enhanced by VEGFR inhibition in a zebrafish xenograft model. J Pathol. 2012;227:431\u201345.","journal-title":"J Pathol"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-021-01926-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-021-01926-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-021-01926-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T15:11:43Z","timestamp":1632409903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-021-01926-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,30]]},"references-count":45,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2021,9,23]]}},"alternative-id":["1926"],"URL":"https:\/\/doi.org\/10.1038\/s41388-021-01926-y","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,30]]},"assertion":[{"value":"1 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}